Stocktoria
Hikma Pharmaceuticals PLC HIK.L
Hikma Pharmaceuticals PLC (HIK.L) earns a Piotroski F-score of 6/9 (mixed financial health), with an Altman Z″ in the safe zone. It pays a dividend yielding 5.78% (safety: moderate). FY2025 revenue was $3.3B at a 12.0% net margin.
Price from month-end closes (Yahoo) — for reference, not real-time.
How it ranks in Healthcare · percentile among 23 companies
Percentile vs other Healthcare companies we cover — e.g. “stronger than 90%” means only 10% score higher on that measure.
Piotroski F breakdown · 6/9 tests passed
- Positive return on assets
- Positive operating cash flow
- Rising ROA
- Cash flow exceeds net income
- Lower long-term debt
- Rising current ratio
- No share dilution
- Rising gross margin
- Rising asset turnover
Altman Z″ components · safe zone
| Component | Value |
|---|---|
| Working capital / assets | 0.21 |
| Retained earnings / assets | 0.451 |
| EBIT / assets | 0.112 |
| Equity / liabilities | 0.846 |
FAQ
Is HIK.L financially healthy?
Hikma Pharmaceuticals PLC's Piotroski F-score is 6/9 (8–9 is excellent, 0–3 weak), and its Altman Z″ distress score is in the safe zone.
Does HIK.L pay a dividend, and is it safe?
Yes. Hikma Pharmaceuticals PLC pays a dividend yielding about 5.78% with a 46.0% payout ratio, rated “moderate” for safety.
How profitable is HIK.L?
In FY2025, Hikma Pharmaceuticals PLC had a net margin of 12.0% and a return on equity of 15.5%.
Source: company filings via Yahoo Finance · GB · as of 2025-12-31. Figures in GBp; non-US fundamentals are aggregated by Yahoo (shorter history); facts plus Stocktoria's own computed scores — not investment advice.